ARCT Stock Summary and Trading Ideas (Arcturus Therapeutics Holdings | NASDAQ:ARCT)

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.

Arcturus Therapeutics Holdings trades on the NASDAQ stock market under the symbol ARCT.

As of April 15, 2024, ARCT stock price declined to $29.31 with 496,737 million shares trading.

ARCT has a beta of 2.44, meaning it tends to be more sensitive to market movements. ARCT has a correlation of 0.21 to the broad based SPY ETF.

ARCT has a market cap of $788.89 million. This is considered a Small Cap stock.

Last quarter Arcturus Therapeutics Holdings reported $34 million in Revenue and -$.32 earnings per share. This fell short of revenue expectation by $-4 million and exceeded earnings estimates by $.67.

In the last 3 years, ARCT stock traded as high as $65.00 and as low as $11.70.

The top ETF exchange traded funds that ARCT belongs to (by Net Assets): ARKG, XBI, VTI, IWM, VXF.

ARCT has underperformed the market in the last year with a price return of +11.7% while the SPY ETF gained +25.3%. ARCT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -11.6% and -13.2%, respectively, while the SPY returned +6.2% and -3.6%, respectively.

ARCT support price is $29.04 and resistance is $31.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARCT stock will trade within this expected range on the day.